The Prognostic Role of Pre-Treatment Neutrophil-to-Lymphocyte Ratio in an Asian Cohort of Patients with Oropharyngeal Squamous Cell Carcinoma

• Published in: Current oncology (Toronto) 2024-11, Vol.31 (11), p.7074-7087
• Main Authors: Jang, Isabelle J H, Abdul Kadir, Hanis B, Lim, Kok Hing, Chew, Wen Chao Daniel, Hwang, Jacqueline S G, Lim, Chwee Ming
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; Carcinoma, Squamous Cell - mortality; Care and treatment; Cohort Studies; Female; head and neck cancer; Humans; Lymphocytes; Male; Middle Aged; neutrophil-to-lymphocyte ratio; Neutrophils; Oropharyngeal Neoplasms - mortality; oropharyngeal squamous cell carcinoma; oropharynx cancer; Prognosis; prognostic factors; Retrospective Studies; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - blood; Squamous Cell Carcinoma of Head and Neck - mortality
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31110521

The neutrophil-to-lymphocyte ratio is a simple biomarker that reflects the balance between the systemic inflammatory and immunity status. Here we investigate the prognostic role of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in an Asian cohort of oropharyngeal squamous cell carcinoma (OPSCC) patients. A retrospective review of OPSCC patients from a tertiary institution was conducted. The NLR was calculated from the haematological specimen taken within a month before treatment. Survival rates were estimated via the Kaplan-Meier method, and Cox proportional hazards regression was performed for univariable and multivariable analyses. The NLR cutpoint was determined using maximally selected log-rank statistics. In a cohort of 148 OPSCC patients, 43% were p16-positive and 44% were p16-negative, with a median follow-up of 24 months. The p16-positive patients were younger (median age 62 vs. 67 years) and exhibited a lower prevalence of heavy smoking (47% vs. 69%). The p16-negative cases frequently presented at an advanced disease stage (74% vs. 41%), with a history of previous radiotherapy (26% vs. 3%). The p16-negative patients displayed a higher median NLR (2.91 vs. 2.49). The 3-year disease-specific survival (DSS) in p16-positive was higher compared to p16-negative patients (89.9% vs. 41.6%). The optimal NLR cutpoint was determined as 3.56 and predicted for decreased DSS (hazard ratio [HR] 2.59, = 0.004). Multivariable analysis revealed smoking, high NLR ≥ 3.56, and p16-negativity as independent variables associated with poorer DSS and overall survival (OS) across the cohort. A high NLR is independently prognostic of poorer DSS in OPSCC, independent of p16 and smoking status. A NLR of more than 3.56 was highly prognostic for poorer survival and warrants further validation in larger cohorts of OPSCC.